Antimetastatic Properties of Low Molecular Weight Heparin [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Laubli, Varki, Borsig Tags: CORRESPONDENCE Source Type: research
Reply to C.S. Hourigan et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Bassan Tags: CORRESPONDENCE Source Type: research
When the Minimal Becomes Measurable [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hourigan, Goswami, Battiwalla, Barrett, Sheela, Karp, Lai Tags: CORRESPONDENCE Source Type: research
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose
To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer.
Methods
ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015. Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events.
Results
Nine randomized controlled trials met the systematic review criteria.
Recommendations
A multiphase computed tomography scan of the abdomen and pelvis ...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Khorana, Mangu, Berlin, Engebretson, Hong, Maitra, Mohile, Mumber, Schulick, Shapiro, Urba, Zeh, Katz Tags: ASCO Guidelines, Diagnosis & Staging, Surgery, Radiation, Chemotherapy ASCO SPECIAL ARTICLE Source Type: research
Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use [STATISTICS IN ONCOLOGY]
The decision curve is a graphical summary recently proposed for assessing the potential clinical impact of risk prediction biomarkers or risk models for recommending treatment or intervention. It was applied recently in an article in Journal of Clinical Oncology to measure the impact of using a genomic risk model for deciding on adjuvant radiation therapy for prostate cancer treated with radical prostatectomy. We illustrate the use of decision curves for evaluating clinical- and biomarker-based models for predicting a man’s risk of prostate cancer, which could be used to guide the decision to biopsy. Decision curves ...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Kerr, Brown, Zhu, Janes Tags: Prognostic Studies, Risk factors STATISTICS IN ONCOLOGY Source Type: research
Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion
%SUVremaining is a predictor for survival and other end points after multimodality treatment and can serve as a parameter for treatment stratification after induction chemotherapy or for evaluation of adjuvant new systemic treatment options for high-risk patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Pottgen, Gauler, Bellendorf, Guberina, Bockisch, Schwenzer, Heinzelmann, Cordes, Schuler, Welter, Stamatis, Friedel, Darwiche, Jockel, Eberhardt, Stuschke Tags: Combined Modality, Nuclear Medicine Thoracic Oncology Source Type: research
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE) [Gynecologic Cancer]
Conclusion
Although the primary objective was not met, subgroup analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Kurzeder, Bover, Marme, Rau, Pautier, Colombo, Lorusso, Ottevanger, Bjurberg, Marth, Barretina-Ginesta, Vergote, Floquet, del Campo, Mahner, Bastiere-Truchot, Martin, Oestergaard, Kiermaier, Schade-Brittinger, Polleis, du Bois, Gonzalez-Martin Tags: Chemotherapy, Combined Modality Gynecologic Cancer Source Type: research
Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia [Pediatric Oncology]
Conclusion
The findings suggest that survivors of ALL should receive counseling regarding lifestyle and undergo screening for hormonal deficits to minimize the risk of low BMD and frailty. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Wilson, Chemaitilly, Jones, Kaste, Srivastava, Ojha, Yasui, Pui, Robison, Hudson, Ness Tags: Long Term Survival & Late Effects Pediatric Oncology Source Type: research
Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study [Gastrointestinal Cancer]
Conclusion
Aspirin use after the diagnosis of CRC is independently associated with improved CSS and OS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Bains, Mahic, Myklebust, Smastuen, Yaqub, Dorum, Bjornbeth, Moller, Brudvik, Tasken Tags: Chemoprevention studies, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Combined Modality, Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia [Hematologic Malignancy]
Conclusion
Patients with cHL who are event free at 2 years have an excellent outcome regardless of baseline prognostic factors. All patients with cHL had an enduring increased risk of death compared with the general population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hapgood, Zheng, Sehn, Villa, Klasa, Gerrie, Shenkier, Scott, Gascoyne, Slack, Parsons, Morris, Pickles, Connors, Savage Tags: Combined Modality Hematologic Malignancy Source Type: research
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma [Hematologic Malignancy]
Conclusion
Enzastaurin did not significantly improve DFS in patients with high-risk DLBCL after achieving complete response to R-CHOP. Achievement of a complete response may have abrogated the prognostic significance of cell of origin by immunohistochemistry. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Crump, Leppa, Fayad, Lee, Di Rocco, Ogura, Hagberg, Schnell, Rifkin, Mackensen, Offner, Pinter-Brown, Smith, Tobinai, Yeh, Hsi, Nguyen, Shi, Hahka-Kemppinen, Thornton, Lin, Kahl, Schmitz, Savage, Habermann Tags: Chemotherapy, Translational Oncology Hematologic Malignancy Source Type: research
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors [Urologic Oncology]
Conclusion
TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs with an acceptable safety profile. Given higher rates of favorable response, progression-free survival, and overall survival compared with prior first-line studies, TIP warrants further study in this population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Feldman, Hu, Dorff, Lim, Patil, Woo, Carousso, Hughes, Sheinfeld, Bains, Daneshmand, Ketchens, Bajorin, Bosl, Quinn, Motzer Tags: Clinical Trials, Chemotherapy Urologic Oncology Source Type: research
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Neurooncology]
Conclusion
The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables. However, both EPN_PFA and EPN_PFB still benefit from increased extent of resection, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy. Patients with EPN_PFB who undergo gross total resection are at lower risk for relapse and should be considered for inclusion in a randomized clinical trial of observation alone with radiation reserved for those who experience recurrence. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Ramaswamy, Hielscher, Mack, Lassaletta, Lin, Pajtler, Jones, Luu, Cavalli, Aldape, Remke, Mynarek, Rutkowski, Gururangan, McLendon, Lipp, Dunham, Hukin, Eisenstat, Fulton, van Landeghem, Santi, van Veelen, Van Meir, Osuka, Fan, Muraszko, Tirapelli, Oba-Sh Tags: Brain Tumors, Surgery, Radiation, Translational Oncology, CNS Tumors, Gene Expression and Profiling Neurooncology Source Type: research
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study [Breast Cancer]
Conclusion
This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC. A single-agent phase II study examining a 200-mg dose given once every 3 weeks (ClinicalTrials.gov identifier: NCT02447003) is ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Nanda, Chow, Dees, Berger, Gupta, Geva, Pusztai, Pathiraja, Aktan, Cheng, Karantza, Buisseret Tags: Chemotherapy, Phase I and Clinical Pharmacology, Breast Imaging Breast Cancer Source Type: research
